DISCUSSION
IBS, depression, fatigue, anxiety
The MY-IBS study is the first to demonstrate the feasibility and safety of an 8-week virtual yoga program combined with the home-based practice for patients with IBS compared with an advice-only control group. The sample had moderate IBS symptom severity at baseline. Significant within-group improvements in IBS symptoms were observed in the treatment group alone at both 4 and 8 weeks after baseline. We did not find significant differences in IBS symptoms between groups postintervention as measured by the IBS-SSS. The response seen in both groups could be explained by the high placebo effect in IBS. Based on a previous meta-analysis of 19 studies examining the placebo response in complementary and alternative medicine trials of IBS, the rate of placebo response was 42.6% (We determined predictors of yoga response using a reduction of 80 points on the IBS-SSS. Fifty-two percent of the treatment participants and 22% of the control participants were classified as responders. One other study (We used a 50-point drop in the IBS-SSS as our primary outcome rather than using the composite outcome mandated by the US Food and Drug Administration for drug trials in IBS (Our study demonstrates beneficial effects of yoga for QOL, fatigue, somatic symptoms, perceived stress, COVID-19–related stress, and self-compassion among patients with IBS. These outcomes were not frequently assessed in the other RCTs. Stress and somatic symptom improvements have been found only in the yoga group in 3 separate RCTs (We did not observe any within-group or between-group differences for anxiety and depression, especially considering the evidence base for yoga for each condition (The yoga intervention in this study was feasible for adherence (79%), attrition rate (20%), and high program satisfaction. Adherence was reported in 3 of the previously described RCTs, varying from 62% to 90% (